Sionna Therapeutics, Inc. (SION)
NASDAQ: SION · Real-Time Price · USD
10.54
-1.03 (-8.87%)
Mar 31, 2025, 3:41 PM EDT - Market open
Company Description
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cystic fibrosis (CF).
It develops nucleotide-binding domain 1 (NBD1) stabilizers that normalize CFTR function for CF patients; Galicaftor (SION-2222) and SION-2851; SION-109, an ICL4-directed CFTR corrector; and Navocaftor (SION-3067), a potentiator.
Sionna Therapeutics, Inc. formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
Sionna Therapeutics, Inc.
| Country | United States |
| Founded | 2019 |
| IPO Date | Feb 7, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Michael Cloonan |
Contact Details
Address: 21 Hickory Drive, Suite 500 Waltham, Massachusetts 02451 United States | |
| Phone | 617 819 2020 |
| Website | sionnatx.com |
Stock Details
| Ticker Symbol | SION |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0002036042 |
| ISIN Number | US8294011080 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael Cloonan, M.B.A. | Chief Executive Officer, President and Director |
| Charlotte McKee, M.D. | Chief Medical Officer |
| Elena Ridloff, C.F.A. | Chief Financial Officer and Head of Corporate Development |
| Paul Clancy, M.B.A. | Chairperson of the Board |
| Bruce Booth, D.Phil. | Director |
| H. Edward Fleming, Jr., M.D. | Director |
| Lucian Iancovici, M.D. | Director |
| Joshua Resnick, M.D., M.B.A. | Director |
| Marcella Kuhlman Ruddy, M.D. | Director |
| Laurie Stelzer, M.B.A. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 20, 2025 | 10-K | Annual Report |
| Mar 20, 2025 | 8-K | Current Report |
| Feb 18, 2025 | SCHEDULE 13D | Filing |
| Feb 18, 2025 | SCHEDULE 13D | Filing |
| Feb 18, 2025 | SCHEDULE 13D | Filing |
| Feb 18, 2025 | SCHEDULE 13D | Filing |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 13, 2025 | SCHEDULE 13D | Filing |
| Feb 10, 2025 | 8-K | Current Report |
| Feb 7, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |